Updates on ValeriusBio's Programs and Activities

ValeriusBio shares selected updates on its research, development programs, and corporate activities. Here we highlight key milestones and other news of interest to partners and investors.

November 2026 - Conferences

ValeriusBio to participate in BIO-Europe in Cologne

ValeriusBio will participate in BIO-Europe in Cologne in November 2026. Our representatives will be available for partnering meetings to discuss the HERAKL1S monovalent antibody platform, and our pipeline of bispecific, monovalent, and Fc-fusion programs. Interested participants can request meetings through the BIO-Europe partnering system. We are looking forward to seeing you in Cologne!

September 2026 - Corporate

ValeriusBio launches new corporate website

ValeriusBio has launched its new corporate website, providing an updated overview of the company’s scientific focus, development pipeline, and HERAKL1S monovalent antibody platform. The site is designed as a central information hub for investors and partners, highlighting ValeriusBio’s approach to antibody engineering and precision medicine.